EN-002

Phase I Main objectives: 1) To evaluate the safety and tolerability of EN002 topical gel in the treatment of non-melanoma skin cancer; Secondary objectives: 1) To evaluate the pharmacokinetic characteristics of EN002 topical gel in subjects with non-melanoma skin cancer; 2) To explore the efficacy of EN002 topical gel in the treatment of non-melanoma skin cancer and provide a basis for the subsequent phase of trial dosing and administration regimen; Phase II Main objectives: 1) To evaluate the anti-tumor efficacy of EN002 topical gel in the treatment of non-melanoma skin cancer and determine the indications; Secondary objectives: 1) To evaluate the efficacy and safety of EN002 topical gel in the treatment of non-melanoma skin cancer; 2) To evaluate the improvement of the quality of life of the subjects.